PLoS Med:患病儿童短期补充营养没有用

2016-02-13 MedSci MedSci原创

 无国界医生(MSF)每年在全球治疗超过三十万名营养不良的儿童。营养不良不仅是由于缺乏食物、幼儿喂养不当,而且还由于疾病。通过给患病儿童提供营养补充来打破疾病和营养不良的恶性循环是一种潜在的有效的策略来预防营养不良,但这一策略仍没有被完全的研究透彻。因此,MSF研究了五岁以下患病儿童的营养不良发病率是否可以在两周的恢复期内降低。为此,研究人员在尼日利亚和乌干达开展了两个临床试验。&nbs

无国界医生(MSF)每年在全球治疗超过三十万名营养不良的儿童。营养不良不仅是由于缺乏食物、幼儿喂养不当,而且还由于疾病。通过给患病儿童提供营养补充来打破疾病和营养不良的恶性循环是一种潜在的有效的策略来预防营养不良,但这一策略仍没有被完全的研究透彻。因此,MSF研究了五岁以下患病儿童的营养不良发病率是否可以在两周的恢复期内降低。为此,研究人员在尼日利亚和乌干达开展了两个临床试验。

MSF研究了即食型治疗食品(RUTF)和一种微量营养素粉(MNP)的补充对于患病儿童营养不良发病率的影响。这是一项部分非盲、随机对照试验。受试儿童被诊断患有疟疾、霍乱或者下呼吸道感染,年龄在6-59个月。受试儿童被随机分为三组:在两周内给予RUTF、MNP或者无补充(对照组)。主要结局是在六个的随访内首次阴性营养结局(NNO)的发病率。NNO是一种研究特异性的测量手段用来研究营养不良的发病率。共有2213人参与此次研究,男女各半。平均年龄为20.2个月,其中有160人最终没有数据,54人住院治疗,29人死亡。

最终的结果表明,经过两周的RUTF或者MNP补充,患病儿童的营养不良发生率没有降低。着主要还是由于补充营养的时间太短或者营养量太少。

原始出处:
van der Kam S, Salse-Ubach N, Roll S, Swarthout T, Gayton-Toyoshima S, et al. (2016) Effect of Short-Term Supplementation with Ready-to-Use Therapeutic Food or Micronutrients for Children after Illness for Prevention of Malnutrition: A Randomised Controlled Trial in Nigeria. PLoS Med 13(2): e1001952. doi: 10.1371/journal.pmed.1001952

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=64811, encodeId=9f0e648115c, content=长期的支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Feb 19 20:42:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606840, encodeId=6738160684017, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 15 07:40:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64264, encodeId=dfb96426453, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:41:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64262, encodeId=1b5764262a4, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64263, encodeId=24936426399, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-19 1de3b290m83(暂无匿称)

    长期的支持

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=64811, encodeId=9f0e648115c, content=长期的支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Feb 19 20:42:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606840, encodeId=6738160684017, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 15 07:40:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64264, encodeId=dfb96426453, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:41:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64262, encodeId=1b5764262a4, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64263, encodeId=24936426399, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=64811, encodeId=9f0e648115c, content=长期的支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Feb 19 20:42:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606840, encodeId=6738160684017, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 15 07:40:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64264, encodeId=dfb96426453, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:41:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64262, encodeId=1b5764262a4, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64263, encodeId=24936426399, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-14 wzf990214

    赞一个

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=64811, encodeId=9f0e648115c, content=长期的支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Feb 19 20:42:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606840, encodeId=6738160684017, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 15 07:40:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64264, encodeId=dfb96426453, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:41:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64262, encodeId=1b5764262a4, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64263, encodeId=24936426399, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-14 wzf990214

    不错哦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=64811, encodeId=9f0e648115c, content=长期的支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Fri Feb 19 20:42:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606840, encodeId=6738160684017, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 15 07:40:00 CST 2016, time=2016-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64264, encodeId=dfb96426453, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:41:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64262, encodeId=1b5764262a4, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64263, encodeId=24936426399, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Sun Feb 14 10:40:00 CST 2016, time=2016-02-14, status=1, ipAttribution=)]
    2016-02-14 wzf990214

    有意思

    0

相关资讯

屠呦呦出席诺奖记者会:三提“工作尚未完成”

12月6日下午,应诺贝尔奖委员会邀请,2015年诺贝尔奖生理学或医学奖得主屠呦呦与爱尔兰科学家威廉·坎贝尔、日本药物科学家大村智一同出席在卡罗林斯卡医学院举行的诺奖得主新闻发布会。图为屠呦呦(右)在与爱尔兰科学家威廉·坎贝尔在交流。沈晨摄 12月6日下午,应诺贝尔奖委员会邀请,2015年诺贝尔奖生理学或医学奖得主屠呦呦(中)与爱尔兰科学家威廉·坎贝尔、日本药物科学家大村智一同出席在卡

NEJM:青蒿琥酯-阿莫地喹联合治疗可能降低埃博拉病毒感染死亡风险

在西非,对于疑似埃博拉病毒感染(EVD)患者都应推荐进行抗疟治疗。佛牙埃博拉病毒感染治疗中心,蒿甲醚–本芴醇(抗疟治疗的一线药物组合)的供应在2014年8月已消耗完12天。这段时间内,患者接受青蒿琥酯-阿莫地喹联合治疗;阿莫地喹是一种体外抗埃博拉病毒活性的药物。使用替换药物治疗期间,患者并未出现其他明显的变化。

Lancet Infect Dis:青蒿琥酯-甲氟喹高效治疗诺氏疟原虫疟疾

 在东南亚地区,诺氏疟原虫已经成为了人患疟疾的最为常见的原因。对于这种感染,目前还没有随机对照试验来确证最佳的治疗方案。因此,研究人员开展了一项非盲、随机对照临床试验来对比青蒿琥酯-甲氟喹和氯喹治疗非复杂性诺氏疟原虫疟疾,从而确定出治疗这一疾病的最佳方案。 临床试验在马来西亚的三个地区医院展开。受试者均是年龄在一岁以上,患有非复杂性诺氏疟原虫疟疾。受试者被随机分配为两组。第一组

NEJM:十年疟疾调查研究报告(针对妊娠期女性)

为达到消除疟疾的目标,除了预防疟疾再感染,还应阻止其再燃,然而目前关于疟疾再燃的不良影响尚不明确。研究者对2003-2012年间分娩的1819名莫桑比克女性进行了研究,估计恶性疟原虫的流行情况。研究者通过镜检、组织活检、qPCR以及流式细胞仪监测对寄生虫的IgG抗体反应情况。研究数据显示,qPCR对恶性疟原虫的检测率从2003年的33%下降到2010年的2%,不过在2012年该值又增加到6%,抗疟

PLOS MED:疟疾感染多数竟然是复发!

 在过去的十五年中,由于全球对疟疾的防控力度加大,许多亚太和美洲的国家疟疾发病数下降了90%,这大大降低了全球的疟疾压力。目前有三十四个国家计划彻底消灭疟疾,其他一些国家也期待在不远的将来实现这一目标。但是目前仍有一个巨大的问题,那就是疟原虫子孢子难以被检测到。尤其是间日疟原虫和卵形疟原虫。这对防控乃至消灭疟原虫造成了巨大的挑战。为此,研究人员在巴布亚新几内亚(PNG)开展调查,从而确定

PLoS Pathog:细胞周期蛋白——根治疟疾有希望啦!

英国诺丁汉大学生命科学学院的科学家们首次发现细胞周期蛋白对推动疟原虫在蚊子体内的增殖至关重要,并将研究结果发表在PLoS Pathogens。研究人员认为,这一发现将有助于人们了解疟原虫在昆虫和人类宿主等体内寄生和增殖,并有利于治疗和遏制该病。 每年世界各地都有数以百万计的人们罹患疟疾,近一百万人因此失去了生命。绝大多数感染和死亡病例发生在撒哈拉以南的非洲地区。 疟疾是由一种叫